Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS

Summary

The OLE study aims to investigate the safety, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod in participants with post-COVID-19 postural orthostatic.

Timeline

Start

2023-06-20

Primary completion

2024-08-15

Completion

2024-08-15

Outcome

Outcome not reported

Stopped: “Due to the phase 2 results of the main study (ARGX-113-2104) showing that efgartigimod-treated PC-POTS patients had no clinically meaningful improvement, the decision has been made to terminate this open-label extension study (ARGX-113-2105) study.”

Drugs

Indications